SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
about
Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer.Glycophenotype of breast and prostate cancer stem cells treated with thieno[2,3-b]pyridine anticancer compound.Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer.Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.Progress in targeted therapy for breast cancer
P2860
SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
SOLTI NeoPARP: a phase II rand ...... triple-negative breast cancer.
@en
SOLTI NeoPARP: a phase II rand ...... triple-negative breast cancer.
@nl
type
label
SOLTI NeoPARP: a phase II rand ...... triple-negative breast cancer.
@en
SOLTI NeoPARP: a phase II rand ...... triple-negative breast cancer.
@nl
prefLabel
SOLTI NeoPARP: a phase II rand ...... triple-negative breast cancer.
@en
SOLTI NeoPARP: a phase II rand ...... triple-negative breast cancer.
@nl
P2093
P2860
P50
P1476
SOLTI NeoPARP: a phase II rand ...... triple-negative breast cancer.
@en
P2093
Antonio Llombart-Cussac
Begoña Bermejo
Claudia Aura
Cristian Villanueva
Eric Charpentier
Henri Roché
Hervé Bonnefoi
Ignacio Garcia-Ribas
Joaquín Gavilá
P2860
P2888
P304
P356
10.1007/S10549-015-3616-8
P407
P577
2015-11-04T00:00:00Z